BACKGROUND: Children presenting with medulloblastoma have a wide range of initial presenting symptoms. However, the influence of underlying tumor biology on the initial presentation of medulloblastoma is currently unknown. In light of the recent discovery of distinct medulloblastoma subgroups, we sought to define the initial presentation of childhood medulloblastoma in a subgroup specific manner. PROCEDURE: We assembled a cohort of 126 medulloblastoma cases at the Hospital for Sick Children between 1994 and 2012 and determined subgroup affiliation using nanoString. Clinical details pertaining to the initial presentation were determined through a retrospective chart review. RESULTS: The median pre-diagnostic interval across all medulloblastoma cases was 4 weeks (IQR: 4-12 weeks). Strikingly, when the pre-diagnostic interval was then determined in a subgroup specific manner, cases with WNT and Group 4 tumors showed significantly longer median pre-diagnostic intervals of 8 weeks compared to 2 weeks for SHH and 4 weeks for Group 3 (P = 0.0001). Younger age was significantly associated with a prolonged pre-diagnostic interval (P = 0.02 for all). When stratifying by subgroup the association with age was only significant in Group 4 (P = 0.04 for Group 4). Improved survival was significantly associated with a longer pre-diagnostic interval (P = 0.02), however is no longer significant when controlling for subgroup (P = 0.07). CONCLUSIONS: The duration of the pre-diagnostic interval in childhood medulloblastoma is highly subgroup dependent, further highlighting the clinical heterogeneity and biological relevance of the four principle subgroups of medulloblastoma.
BACKGROUND:Children presenting with medulloblastoma have a wide range of initial presenting symptoms. However, the influence of underlying tumor biology on the initial presentation of medulloblastoma is currently unknown. In light of the recent discovery of distinct medulloblastoma subgroups, we sought to define the initial presentation of childhood medulloblastoma in a subgroup specific manner. PROCEDURE: We assembled a cohort of 126 medulloblastoma cases at the Hospital for Sick Children between 1994 and 2012 and determined subgroup affiliation using nanoString. Clinical details pertaining to the initial presentation were determined through a retrospective chart review. RESULTS: The median pre-diagnostic interval across all medulloblastoma cases was 4 weeks (IQR: 4-12 weeks). Strikingly, when the pre-diagnostic interval was then determined in a subgroup specific manner, cases with WNT and Group 4 tumors showed significantly longer median pre-diagnostic intervals of 8 weeks compared to 2 weeks for SHH and 4 weeks for Group 3 (P = 0.0001). Younger age was significantly associated with a prolonged pre-diagnostic interval (P = 0.02 for all). When stratifying by subgroup the association with age was only significant in Group 4 (P = 0.04 for Group 4). Improved survival was significantly associated with a longer pre-diagnostic interval (P = 0.02), however is no longer significant when controlling for subgroup (P = 0.07). CONCLUSIONS: The duration of the pre-diagnostic interval in childhood medulloblastoma is highly subgroup dependent, further highlighting the clinical heterogeneity and biological relevance of the four principle subgroups of medulloblastoma.
Authors: Yuan Y Thompson; Vijay Ramaswamy; Phedias Diamandis; Craig Daniels; Michael D Taylor Journal: Childs Nerv Syst Date: 2015-09-09 Impact factor: 1.475
Authors: Vijay Ramaswamy; Marc Remke; Jennifer Adamski; Ute Bartels; Uri Tabori; Xin Wang; Annie Huang; Cynthia Hawkins; Donald Mabbott; Normand Laperriere; Michael D Taylor; Eric Bouffet Journal: Neuro Oncol Date: 2015-01-20 Impact factor: 12.300
Authors: Michael Zhang; Samuel W Wong; Jason N Wright; Matthias W Wagner; Sebastian Toescu; Michelle Han; Lydia T Tam; Quan Zhou; Saman S Ahmadian; Katie Shpanskaya; Seth Lummus; Hollie Lai; Azam Eghbal; Alireza Radmanesh; Jordan Nemelka; Stephen Harward; Michael Malinzak; Suzanne Laughlin; Sébastien Perreault; Kristina R M Braun; Robert M Lober; Yoon Jae Cho; Birgit Ertl-Wagner; Chang Y Ho; Kshitij Mankad; Hannes Vogel; Samuel H Cheshier; Thomas S Jacques; Kristian Aquilina; Paul G Fisher; Michael Taylor; Tina Poussaint; Nicholas A Vitanza; Gerald A Grant; Stefan Pfister; Eric Thompson; Alok Jaju; Vijay Ramaswamy; Kristen W Yeom Journal: Radiology Date: 2022-04-19 Impact factor: 29.146
Authors: Rashad Jabarkheel; Nisreen Amayiri; Derek Yecies; Yuhao Huang; Sebastian Toescu; Liana Nobre; Donald J Mabbott; Sniya V Sudhakar; Prateek Malik; Suzanne Laughlin; Maisa Swaidan; Maysa Al Hussaini; Awni Musharbash; Geeta Chacko; Leni G Mathew; Paul G Fisher; Darren Hargrave; Ute Bartels; Uri Tabori; Stefan M Pfister; Kristian Aquilina; Michael D Taylor; Gerald A Grant; Eric Bouffet; Kshitij Mankad; Kristen W Yeom; Vijay Ramaswamy Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300
Authors: Xin Wang; Borja L Holgado; Vijay Ramaswamy; Stephen Mack; Kory Zayne; Marc Remke; Xiaochong Wu; Livia Garzia; Craig Daniels; Anna M Kenney; Michael D Taylor Journal: Neuro Oncol Date: 2018-02-19 Impact factor: 12.300
Authors: Eric M Thompson; Thomas Hielscher; Eric Bouffet; Marc Remke; Betty Luu; Sridharan Gururangan; Roger E McLendon; Darell D Bigner; Eric S Lipp; Sebastien Perreault; Yoon-Jae Cho; Gerald Grant; Seung-Ki Kim; Ji Yeoun Lee; Amulya A Nageswara Rao; Caterina Giannini; Kay Ka Wai Li; Ho-Keung Ng; Yu Yao; Toshihiro Kumabe; Teiji Tominaga; Wieslawa A Grajkowska; Marta Perek-Polnik; David C Y Low; Wan Tew Seow; Kenneth T E Chang; Jaume Mora; Ian F Pollack; Ronald L Hamilton; Sarah Leary; Andrew S Moore; Wendy J Ingram; Andrew R Hallahan; Anne Jouvet; Michelle Fèvre-Montange; Alexandre Vasiljevic; Cecile Faure-Conter; Tomoko Shofuda; Naoki Kagawa; Naoya Hashimoto; Nada Jabado; Alexander G Weil; Tenzin Gayden; Takafumi Wataya; Tarek Shalaby; Michael Grotzer; Karel Zitterbart; Jaroslav Sterba; Leos Kren; Tibor Hortobágyi; Almos Klekner; Bognár László; Tímea Pócza; Peter Hauser; Ulrich Schüller; Shin Jung; Woo-Youl Jang; Pim J French; Johan M Kros; Marie-Lise C van Veelen; Luca Massimi; Jeffrey R Leonard; Joshua B Rubin; Rajeev Vibhakar; Lola B Chambless; Michael K Cooper; Reid C Thompson; Claudia C Faria; Alice Carvalho; Sofia Nunes; José Pimentel; Xing Fan; Karin M Muraszko; Enrique López-Aguilar; David Lyden; Livia Garzia; David J H Shih; Noriyuki Kijima; Christian Schneider; Jennifer Adamski; Paul A Northcott; Marcel Kool; David T W Jones; Jennifer A Chan; Ana Nikolic; Maria Luisa Garre; Erwin G Van Meir; Satoru Osuka; Jeffrey J Olson; Arman Jahangiri; Brandyn A Castro; Nalin Gupta; William A Weiss; Iska Moxon-Emre; Donald J Mabbott; Alvaro Lassaletta; Cynthia E Hawkins; Uri Tabori; James Drake; Abhaya Kulkarni; Peter Dirks; James T Rutka; Andrey Korshunov; Stefan M Pfister; Roger J Packer; Vijay Ramaswamy; Michael D Taylor Journal: Lancet Oncol Date: 2016-03-12 Impact factor: 41.316